The US Food and Drug Administration (FDA) has accepted a pre-market tobacco product application from TJP Labs for its L!X nicotine pouch product for review.
TJP Labs has created the L!X nicotine pouch for adult users (21 years and older) who are unable or unwilling to quit using nicotine products, particularly those who wish to transition to non-combustible oral products, according to a statement by TJP Labs CEO David Richmond-Peck.
He said, "The acceptance of our application by the FDA shows our team's dedication to providing alternative products for adult users that may reduce harm associated with traditional combustible tobacco products. Our factory's Canadian Health Department drug establishment license (DEL), natural health product site license, ISO 9001:2015, HACCP, and cGMP certifications demonstrate TJP Labs' strict quality standards and will further enhance our ability to serve the high-volume international market.
TJP Labs is a top-tier full-service contract manufacturer for next-generation products, specializing in oral nicotine pouches, caffeine, and other health supplements delivery solutions. The company is headquartered in Pickering, Ontario, Canada.
The L!X nicotine pouches are sold by L!X Innovations, a subsidiary of TJP Lab.
This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.
